Farrera-Sal Martí, Moya-Borrego Laura, Bazan-Peregrino Miriam, Alemany Ramon
ProCure Program, IDIBELL-Institut Català d'Oncologia, Barcelona, Spain.
VCN Biosciences SL, Barcelona, Spain.
Clin Cancer Res. 2021 Jun 1;27(11):2979-2988. doi: 10.1158/1078-0432.CCR-20-1565. Epub 2021 Feb 1.
Cancer immunotherapy targeting immune checkpoint inhibitors shows efficacy in several human cancers, but "cold tumors" that lack immune cells are typically unresponsive. Among the potential therapeutic approaches that could "heat" or promote lymphocyte infiltration of cold tumors, oncolytic viruses have attracted interest for their lytic and immunogenic mechanisms of action. In this article, we review the use of oncolytic adenoviruses in cancer immunotherapy, with a particular focus on preclinical and clinical data of oncolytic adenovirus-triggered immune responses against tumor antigens. We also discuss parameters to consider in clinical trial design and the combination of oncolytic adenoviruses with conventional treatments or other immunotherapies.
针对免疫检查点抑制剂的癌症免疫疗法在多种人类癌症中显示出疗效，但缺乏免疫细胞的“冷肿瘤”通常无反应。在可能“加热”或促进冷肿瘤淋巴细胞浸润的潜在治疗方法中，溶瘤病毒因其溶瘤和免疫原性作用机制而备受关注。在本文中，我们综述了溶瘤腺病毒在癌症免疫疗法中的应用，特别关注溶瘤腺病毒引发针对肿瘤抗原的免疫反应的临床前和临床数据。我们还讨论了临床试验设计中需要考虑的参数，以及溶瘤腺病毒与传统治疗或其他免疫疗法的联合应用。
